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Abstract
The molecular mechanism and regulation of the intestinal uptake process of dietary thiamine is not well understood.
Previous studies have established the involvement of a carrier-mediated system for thiamine uptake in the human intestine.
Recently a human thiamine transporter, SLC19A2, was cloned from a number of human tissues. Little, however, is known
about expression of the SLC19A2 message along the native human gastrointestinal tract, and no analysis of its promoter in
intestinal tissue is available. Therefore, the current studies were aimed at investigating the expression of SLC19A2 in the
human gastrointestinal tract and at analyzing the promoter of this potential intestinal thiamine transporter. First we cloned
SLC19A2 cDNA from a human intestinal cell line (Caco-2) by reverse transcriptase^polymerase chain reaction, then used
this cDNA as a probe in Northern blot analysis. SLC19A2 message was found to be expressed in all gastrointestinal tissues
in the following order: livers stomachs duodenums jejunums colons cecums rectums ileum. SLC19A2 was also
expressed at the protein level in Caco-2 cells and in native human small intestine by Western blot analysis. We also cloned
the 5P-regulatory region of the SLC19A2 gene and confirmed activity of its promoter following transfection into intestinal
epithelial Caco-2 cells. Furthermore, we identified the minimal promoter region required for basal activity of SLC19A2 in
these cells which was found to be mainly encoded in a sequence between 3356 and 336, and included multiple cis-
regulatory elements. Transcription initiation sites of the SLC19A2 gene in intestinal epithelial Caco-2 cells were also
identified by 5P-rapid amplification of cDNA ends. These results demonstrate that SLC19A2 is expressed in various regions
of the human gastrointestinal tract. In addition, the results provide the first characterization of the SLC19A2 promoter.
These findings raise the possibility that SLC19A2 may play a role in the normal intestinal thiamine absorption
process. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The water-soluble vitamin thiamine (B1) is an es-
sential micronutrient for normal cellular function,
growth, and development. Thiamine pyrophosphate,
the coenzyme form of the vitamin, plays an impor-
tant role in carbohydrate metabolism [1]. Nutritional
de¢ciencies of thiamine can lead to cardiovascular
and neurological disorders [1^3]. Cardiovascular dis-
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orders include peripheral vasodilation, biventricular
myocardial failure, edema, and potentially acute ful-
minant cardiovascular collapse. Neurological disor-
ders that have been observed are confusion, disor-
dered ocular motility, neuropathy, and ataxia of
gait. Thiamine de¢ciency also occurs in alcoholics
[3^6], diabetics [7], coeliac and renal disease patients
[8], the elderly [9], and individuals on long term diu-
retic medications [10]. Furthermore, patients with
thiamine-responsive megaloblastic anemia (TRMA),
an autosomal recessive disorder characterized by
manifestations that include sensorineural deafness,
and diabetes mellitus, respond in varying degrees to
thiamine treatment [11,12].
Humans and other mammals have lost their abil-
ity to synthesize thiamine, and thus, must obtain the
vitamin from exogenous sources. Intestinal absorp-
tion is the initial site of uptake and therefore must
play a critical role in regulating thiamine body ho-
meostasis. Thus, understanding the molecular mech-
anism(s) and regulation of thiamine uptake in the
intestine is of signi¢cant importance. Previous stud-
ies using a variety of human and animal intestinal
preparations have established the involvement of a
specialized carrier-mediated mechanism for thiamine
uptake ([13,14] and references therein). Our labora-
tory has shown that puri¢ed human brush border
membrane vesicles and cultured human intestinal
epithelial cells also posses a carrier-mediated system
for thiamine uptake [15^17]. Several groups have
recently identi¢ed a human thiamine transporter,
SLC19A2, which is predicted to encode a multi-
transmembrane vitamin transport protein [18^21].
A mouse orthologue (Slc19a2) to the human thi-
amine transporter has also been recently identi¢ed
[22]. When the SLC19A2 cDNA is expressed in
mammalian cells, it speci¢cally induced thiamine
uptake [19]. Little, however, is known about expres-
sion of this gene in the di¡erent regions of the hu-
man gastrointestinal tract, and no information is
available about its 5P-regulatory region. The results
of our current study demonstrate that the SLC19A2
message is expressed in di¡erent regions of the hu-
man gastrointestinal tract. In addition, the results
provide the ¢rst characterization of the 5P-regula-
tory region of the human SLC19A2 gene, and iden-
tify the minimal region required for its basal activ-
ity.
2. Materials and methods
2.1. Materials
Restriction enzymes were purchased from New
England Biolabs (Beverly, MA). DNA polymerase
was purchased from Clontech (Palo Alto, CA). Rou-
tine biochemicals were all of molecular biology qual-
ity, and purchased from Fisher Scienti¢c Corp. (Tus-
tin, CA). Cell culture reagents were purchased from
Sigma Chemical Co. (St. Louis, MO), and Life Tech-
nologies (Rockville, MD). Fetal bovine serum (FBS)
was obtained from Omega Scienti¢c (Tarzana, CA).
DNA oligonucleotide primers were purchased from
Sigma Genosys (Woodlands, TX).
2.2. Cloning of the SLC19A2 cDNA from
Caco-2 cells
The SLC19A2 cDNA was cloned from Caco-2
cells by reverse transcriptase^polymerase chain reac-
tion (RT^PCR). Brie£y, poly(A) RNA isolated
from Caco-2 cells was primed with a gene speci¢c
primer 5P-GCTGCTGTGAAGTCAAGAAAT-3P to
generate ¢rst-strand cDNA using an RT^PCR kit
(Life Technologies). The RT^PCR product was sub-
sequently used in a PCR with the same reverse prim-
er, and a gene-speci¢c forward primer 5P-CGCG-
CCCCGGATGGATGT-3P (see Table 2 for the
position of the primers). The nucleotide sequence
of the resulting PCR product was determined by se-
quencing using a commercial vendor (Seqwright,
Houston, TX) and found to be identical to the
open reading frame (ORF) of SLC19A2 [18^21].
2.3. Northern and Western blot analysis
Northern blot analysis was performed as previ-
ously described [16]. The full-length ORF SLC19A2
clone from Caco-2 cells was randomly labeled with
[32P]dCTP, and used as a probe on a commercially
available blot that contained poly(A) RNA (2 Wg)
from di¡erent regions of the human digestive tract
(Clontech). The probe was simultaneously used on a
blot containing an equivalent amount of poly(A)
RNA (2 Wg) isolated from Caco-2 cells. The blots
were stripped and reprobed with a labeled human
L-actin cDNA. SLC19A2 message level was normal-
BBAMEM 78223 26-4-02
J.C. Reidling et al. / Biochimica et Biophysica Acta 1561 (2002) 180^187 181
ized relative to the L-actin signal using the Eagle Eye
II densitometer (Stratagene). Western blot analysis
was performed as previously described [16] using a
speci¢c antibody to the SLC19A2 protein on Caco-2
cells and puri¢ed human intestinal brush border
membranes. Brush border membranes were prepared
from the jejunum of organ donors as previously de-
scribed [15]).
2.4. 5P-RACE
The rapid ampli¢cation of cDNA ends (RACE)
was performed using the 5P-RACE Version 2.0 kit
purchased from Life Technologies. The manufactur-
er’s protocols were followed for all reactions. Two
micrograms of RNA isolated from Caco-2 cells was
used with the gene speci¢c reverse primer GSP8R in
the initial RT^PCR. The ¢rst-strand cDNA was iso-
lated and tailed. The PCR of tailed cDNA was then
performed using the manufacturer’s Abridged An-
chor Primer and the gene-speci¢c reverse primer
GSP9R. A subsequent nested ampli¢cation was per-
formed using the manufacturer’s AUAP primer and
the gene-speci¢c reverse primer R4. PCR products
were analyzed on a 3% agarose gel in TAE bu¡er,
extracted from the gel, puri¢ed using the gene-clean
II kit (Bio101, Carlsbad, CA), subcloned into the
pGEM-T Easy vector (Promega, Madison, WI) and
Table 1
Preparation of the promoter and promoter deletion constructs
Construct name Enzyme/primers Position Size
pGL3-P KpnI 32250 to 336 2214
pGL3-Pv1 NruI 32179 to 336 2143
pGL3-Pv2 NdeI 31645 to 336 1609
pGL3-Pv3 PvuII 3450 to 336 414
pGL3-Pv4 F7/GSP9 3429 to 336 393
pGlL3-Pv5 AatII 3356 to 336 320
pGL3-Pv6 F6/GSP9 3317 to 336 281
pGL3-Pv7 F3/GSP9 3275 to 336 239
pGL3-Pv8 F4/GSP9 3139 to 336 103
pGL3-Pv9 F5/GSP9 3108 to 336 72
The relative position of the SLC19A2 gene sequence is based on numbering the A of the translation initiation codon as 1 with up-
stream sequences indicated as negative numbers.
Table 2
Sequence of primers used in PCR
Primer name Sequence (5P^3P) Position
ORF F CGCGCCCCGGATGGATGT 314 to 4
ORF R GCTGCTGTGAAGTCAAGAAAT 1594 to 1615
GSP8 R GGCAAGAACCAGCATTCG 76 to 93
GSP9 R ACGTAAAGCTT CCCCTTCCTTCTCCTCCTC 354 to 336
R4 ACGTAAAGCTT CGCCGCCTCCGGCTACA 3152 to 3135
GSP6 F TATTACCACATCAGCTTAGCTCACA 32922 to 32898
GSP7 F ACGTACTCGAGTATGTAGCCCCCTCCAACA 32669 to 32650
F7 TATCGGTACCAGAGAGCTCCGCCGCAAG 3429 to 3412
F6 TATCGGTACCTGTGACCCACGACCAATG 3317 to 3300
F3 TATCGGTACCGTCCGCTGTGATTGGTTC 3275 to 3258
F4 TATCGGTACCCGGCGGCGAGTCCAGAAC 3139 to 3125
F5 TATCGGTACCAGGGAGAAGGCGTCACTC 3108 to 391
The HindIII site is underlined, the XhoI site is italic, and the KpnI site is double underlined. The position number of the primers only
represents the matching sequence in the 5P-regulatory region of the SLC19A2 gene not including the added restriction sites, and is
therefore not re£ective of primer size. The relative position of the SLC19A2 gene sequence is based on numbering the A of the trans-
lation initiation codon as 1 with upstream sequences indicated as negative numbers.
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the sequence was veri¢ed by the University of Cal-
ifornia, Irvine (UCI) core DNA sequencing facility.
See Table 2 for the sequence and position of the
primers.
2.5. Cloning of the 5P-regulatory region for the
SLC19A2 gene
To obtain the genomic DNA fragment that con-
tained the 5P-regulatory region of the SLC19A2 gene
we utilized the sequence information deposited in
GenBank (accession number AL021068) for the
SLC19A2 gene and £anking sequence. A PCR was
then performed using two gene-speci¢c primers
(GSP6F and GSP8R, Table 2) and 100 ng of human
genomic DNA (Invitrogen). A reaction bu¡er and
polymerase specially developed to allow ampli¢ca-
tion through GC-rich regions in the DNA sequence
was used (Advantage GC Genomic PCR kit; Clon-
tech). PCR conditions were denaturation at 95‡C for
5 min, followed by 30 cycles of denaturation at 95‡C
for 30 s, annealing at 50‡C for 30 s, and extension at
72‡C for 4 min, then a ¢nal extension at 72‡C for 15
min. The 3005 basepair (bp) product was run on a
0.7% agarose gel and puri¢ed. The puri¢ed DNA
was then used in a second PCR with nested primers
(GSP7F and GSP9R, Table 2) and the same reaction
conditions described above. The resulting product of
size 2635 bp was puri¢ed as described above, sub-
cloned into the pGEM-T Easy vector (Promega) and
the DNA sequence was veri¢ed (see below).
2.6. Preparation of promoter^luciferase and deletion
constructs of the SLC19A2 promoter
The 2635 bp PCR product obtained above was
digested with the restriction enzymes XhoI and Hin-
dIII (these sites were designed into the nested primers
used in the ¢nal PCR, Table 2) and subcloned into
the pGL3-Basic vector (Promega) digested with the
same restriction enzymes. This places the PCR prod-
uct upstream of the promoter-less luciferase gene for
promoter activity analysis. Several deletions were
then made using restriction sites common to both
the subcloned PCR product and the pGL3-Basic vec-
tor multiple cloning site or using gene-speci¢c for-
ward primers and the GSP9R primer (Tables 1 and
2). To generate the deletions using restriction en-
zymes, the subcloned pGL3-Basic construct was di-
gested with a speci¢c restriction enzyme, agarose gel
puri¢ed as described above and re-ligated using the
Rapid Ligation Kit (Roche, Indianapolis, IN). To
generate more deletion constructs gene-speci¢c prim-
ers (Tables 1 and 2) were used in a PCR with the
2635 bp subclone-pGL3-Basic construct described
above as a template. The PCR products were puri-
¢ed and subsequently subcloned into the KpnI and
HindIII sites of the pGL3-Basic vector. All con-
structs were veri¢ed with DNA sequencing using
the UCI core sequencing facility. See Table 1 for
restriction sites, primers, and sizes of deletions. See
Table 2 for the sequence and position of the primers.
2.7. Cell culture, transfection, and luciferase assay
Four Wg of each of the constructs in Table 1 were
transfected separately into human intestinal Caco-2
cells using the Lipofectamine reagent (Life Technol-
ogies, Gaithersburg, MD) and the manufacturer’s
procedure. To normalize for transfection e⁄ciency,
the cells were co-transfected with 100 ng of pRL-TK
(Promega) plasmid along with the promoter con-
structs. Total cell lysate was prepared from cells 24
h post transfection and ¢re£y luciferase activity was
assayed using the Dual Luciferase Kit (Promega) and
a Turner Design 20/20 Luminometer (Sunnyvale,
CA). The activity was normalized to the Renilla lu-
ciferase activity from pRL-TK in the same extract.
Data presented are mean þ S.E.M. of at least three
independent experiments and given as fold expres-
sion over pGL3-Basic expression set arbitrarily at
1. Statistical analysis was performed using Student’s
t-test.
3. Results
3.1. Cloning of the SLC19A2 cDNA from human
intestinal epithelial Caco-2 cells and expression in
di¡erent regions of the gastrointestinal tract
In this study, we ¢rst cloned the SLC19A2 cDNA
from Caco-2 cells, then used it as a probe to deter-
mine the relative distribution of the message along
the native human gastrointestinal tract. cDNA was
cloned by RT^PCR using gene-speci¢c primers de-
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signed to detect the ORF of the published SLC19A2
sequence [21]. The identity of the obtained cDNA
was con¢rmed by sequencing and found to match
the published sequence of the SLC19A2 predicted
ORF. Distribution of the SLC19A2 message was as-
sessed by Northern blot analysis using the cloned
SLC19A2 cDNA as a probe and a commercially
available blot that contained poly(A) RNA (2 Wg)
from di¡erent regions of the human digestive tract
(Clontech). A blot containing an equivalent amount
of Caco-2 poly(A) RNA (2 Wg) was simultaneously
probed. The results showed that the SLC19A2 mes-
sage was expressed in all gastrointestinal regions ex-
amined as well as in Caco-2 cells (Fig. 1); expression
level was as follows: livers stomachs duode-
nums jejunums colons cecumsCaco-2 = rectum -
s ileum. Not only SLC19A2 RNA, but also the cor-
responding protein was found to be expressed in
Caco-2 cells and in native human small intestine (je-
junal brush border membranes were isolated from
organ donors as described previously, [15]) as shown
by Western blot analysis using polyclonal antibodies
raised against a speci¢c peptide of the SLC19A2 pro-
tein [16] (Fig. 2).
3.2. Determination of the transcription initiation site
for SLC19A2 in intestinal Caco-2 cells using
5P-RACE
Transcription initiation site(s) for SLC19A2 in in-
testinal Caco-2 cells was identi¢ed using 5P-RACE as
described in Section 2. Two clones for each products
isolated from independent 5P RACE reactions were
sequenced. The results showed the potential existence
of three transcription initiation sites for SLC19A2 in
Caco-2 cells, one begins at position 3183, another at
3192 and the last at 3220 using the A in the initia-
tor ATG sequence as position 1.
3.3. Cloning of the 5P-regulatory region of the human
SLC19A2 gene and determining promoter activity
in intestinal epithelial Caco-2 cells
Using primers designed to the published sequence
for the SLC19A2 gene and £anking sequence, we
isolated a 2635 bp DNA fragment from the 5P-regu-
latory region. The identity of the genomic DNA
fragment was established by sequencing. To verify
the functionality of the putative human promoter,
we prepared a construct placing the DNA fragment
in the promoter-less pGL3-Basic vector for use in the
dual luciferase system (Promega), described previ-
ously [23]. The promoter activity was determined
by analysis of the luciferase activity in transiently
transfected Caco-2 cells. The 2635 bp fragment was
determined to have signi¢cant promoter activity us-
ing the luciferase system. To determine the minimal
region required for basal activity of the promoter, we
generated a series of deletion fragments fused to the
¢re£y luciferase reporter gene (see Tables 1 and 2)
and found that activity was con¢ned mainly to a
sequence between 3356 and 336, using the A of
the initiation codon as position 1 (see Fig. 3,
Fig. 2. Expression of the SLC19A2 protein in Caco-2 cells and
in native human intestinal tissue. Western blot analysis contain-
ing 150 Wg of protein from a membrane fraction isolate of
Caco-2 cells and 150 Wg of protein from human jejunal brush
border membranes. The blot was probed with a polyclonal anti-
body directed against a speci¢c peptide corresponding to the
SLC19A2 protein and detected using the ECL system.
Fig. 1. Expression of SLC19A2 along the native human gastro-
intestinal tract, liver, and Caco-2. Northern blots containing
2 Wg/lane of poly(A) RNA isolated from the listed native tis-
sues of the human digestive system (Clontech) and 2 Wg poly
(A) RNA from Caco-2 cells simultaneously probed with ran-
domly labeled SLC19A2 cDNA. The blots were stripped and
reprobed with a labeled human L-actin cDNA. SLC19A2 mes-
sage level was normalized relative to the L-actin signal using
the Eagle Eye II densitometer (Stratagene).
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pGL3-Pv5). A further deletion of 39 bp resulted in
an approximate 50% reduction in activity, pGL3-Pv6
(Fig. 3), and a deletion of another 42 bp nearly abol-
ished activity, pGL3-Pv7 (Fig. 3). The identi¢ed pu-
tative promoter region was found to have a CAAT
box at position 3305 but no classical TATA ele-
ments at the expected positions. We analyzed the
minimal region of the promoter (3356 to 336) for
transcription factor binding sites using the TRANS-
FAC program [24] and found several putative regu-
latory elements including, Nuclear Factor-1 (NF1),
Activator Protein-1 (AP1), Gut enriched Krupple-
like Factor (GKLF), and Stimulating Protein-1
(SP1) (Fig. 4). The roles of these putative cis-ele-
ments in the transcriptional regulation of SLC19A2
are currently under investigation in our laboratory.
4. Discussion
Despite the existence of a signi¢cant body of work
on the physiological and biochemical aspects of the
intestinal thiamine uptake process, little is known
about the molecular characteristics of the absorption
event. Recently a human thiamine transporter,
SLC19A2, has been cloned from a number of human
tissues [18^21], but very little is known about expres-
sion of this gene in native tissues of the human gas-
trointestinal tract, and no information is available
about its 5P regulatory region. In this study, we ¢rst
cloned the SLC19A2 cDNA from the human derived
intestinal epithelial Caco-2 cells by RT^PCR, then
determined expression of the SLC19A2 message in
di¡erent tissues of the native gastrointestinal tract
and the liver. Our cloning e¡ort produced a cDNA
identical to that of SLC19A2 [18^21]. This ¢nding
clearly shows that SLC19A2 is expressed in this hu-
man intestinal epithelial cell line. Using this cDNA
as a probe, we then determined the relative expres-
sion of the SLC19A2 message along the native hu-
Fig. 4. Diagrammatic representation of the minimal 5P-region
of the SLC19A2 gene required for basal promoter activity. The
nucleotide sequence of the minimal region required for basal
activity in Fig. 3 is shown. Boxes indicate the positions of sev-
eral identi¢ed putative regulatory elements. The nucleotides of
the three transcription initiation sites are underlined. Numbers
represent nucleotides relative to the translational start site A of
ATG as number 1. Primers used in making deletion constructs
are shown in bold (Tables 1 and 2).
Fig. 3. Functional analysis and identi¢cation of the minimal region required for basal activity of the SLC19A2 putative promoter.
The size and position of di¡erent promoter^luciferase constructs are shown on the left. The results of a luciferase assay for each con-
struct following transient transfection into human intestinal Caco-2 cells is shown on the right. Fire£y luciferase activity was normal-
ized relative to the activity of simultaneously expressed Renilla luciferase. The results are expressed relative to the pGL3-Basic vector
set at 1 and represent the average of at least three independent experiments.
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man gastrointestinal tract and the liver by Northern
blot analysis. The SLC19A2 message was found to
be expressed in all regions of the digestive system
examined in the following order: livers stomach
s duodenum s jejunum s colon s cecum s
Caco-2 = rectums ileum. We also con¢rmed the ex-
pression of SLC19A2 in Caco-2 cells as well as native
human small intestinal mucosa at the protein level
using Western blot analysis with antibodies speci¢c
to the transporter. Functionality of the human intes-
tinal cDNA was con¢rmed in our laboratory by ex-
pression in Xenopus oocytes and HeLa cells (unpub-
lished observations) with results similar to those
described previously [9].
Previous work in our laboratory and others has
described the mechanism and regulation of thiamine
uptake in human intestinal Caco-2 cells and other
human intestinal preparations [15^17,25,26]. As men-
tioned above, the characteristics of thiamine trans-
port in Caco-2 cells and other human intestinal prep-
arations are very similar to those reported for HeLa
cells transfected with a SLC19A2 cDNA ([19], and
unpublished observations in our laboratory). These
characteristics include similar apparent Km, Na in-
dependence, thiamine substrate speci¢city, pH pro-
¢le, and a lack of a¡ect of unrelated organic cations
on thiamine uptake. In addition, we have recently
been able to detect the expression of the SLC19A2
message in rat enterocytes (unpublished observa-
tions). Furthermore, a recent study by Fleming et
al. [27] has also reported expression of the mouse
orthologue (Slc19a2) of the thiamine transporter in
the mouse intestine. Collectively, the above described
¢ndings raise the possibility that SLC19A2 may play
a role in normal intestinal thiamine uptake process.
Further characterization of the SLC19A2 message
in intestinal epithelial Caco-2 cells revealed multiple
transcription initiation sites. This conclusion is based
on results of the 5P-RACE analysis using RNA iso-
lated from these cells. In a related study, we cloned
the 5P-regulatory region for the SLC19A2 gene and
showed the region to have signi¢cant promoter ac-
tivity following transfection into human intestinal
Caco-2 cells. The identi¢ed promoter region does
not appear to be interrupted with alternative exon
sequences and our genomic clone included one con-
tinuous sequence containing all published 5P-untrans-
lated region sequences [18^21]. We have also identi-
¢ed the minimal promoter region required for its
basal activity and found it to be encoded in a se-
quence between 3356 and 336. The identi¢ed pro-
moter region was found to have a CAAT box at
position 3305 but no classical TATA elements at
the expected position, typical for a so called house-
keeping gene. The 320 bp region is GC-rich at 64%
and has several putative cis-elements including NF1,
AP1, GKLF, and SP1which may be involved in the
regulation of transcription of the SLC19A2 gene. It
is worth mentioning here that a recent study using
computational analysis of the 5P-regulatory region of
the mouse Slc19a2 gene has also reported the exis-
tence of similar promoter cis-elements to those de-
scribed above for the human gene [22].
The ¢ndings described above of signi¢cant
promoter activity for SLC19A2 in Caco-2 cells
further demonstrate the ability of the human intes-
tine to express this thiamine transporter. In sum-
mary, our study shows that SLC19A2 is expressed
in di¡erent regions of the native human gastrointes-
tinal tract. The results also describe, for the ¢rst
time, characterization of the 5P-regulatory region
of this gene and identify the minimal promoter re-
gion required for its basal activity. This should serve
as a basis for future investigation into the molecular
regulation of this potential human intestinal thi-
amine transporter.
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